Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisI

Does β-blocker prophylaxis improve survival after major noncardiac surgery?

Marius Terblanche, Neill K.J. Adhikari and Damon C. Scales
CMAJ October 11, 2005 173 (8) 874; DOI: https://doi.org/10.1503/cmaj.051134
Marius Terblanche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neill K.J. Adhikari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damon C. Scales
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349-61.

Background: The value of prophylactic β-blockade in reducing morbidity and mortality after major noncardiac surgery remains controversial, although limited evidence and several guidelines favour this approach.

Design: A U.S. database was used to retrospectively identify adult patients who underwent major noncardiac surgery. Using a propensity score that was calculated to reflect the likelihood of receiving prophylactic β-blockade therapy, 119 632 patients who took β-blockers during the first 2 days of hospital admission were matched with 216 290 patients who did not. In-hospital mortality was compared using logistic regression, incorporating the propensity score to adjust for potential between-group differences.

Results: Overall, 18% of patients received β-blockers, including 14% of patients at very low risk of death (Revised Cardiac Risk Index [RCRI] score of 0) and 44% of patients at high risk (RCRI ≥ 4). The relation between perioperative β-blockade therapy and the risk of death varied with cardiac risk. Among low-risk patients (RCRI ≤ 1), therapy was associated with no benefit and possible harm, whereas for higher-risk patients (RCRI ≥ 2), therapy reduced the risk of death, with the benefit increasing with increasing baseline risk (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Commentary: The most important threat to the validity of this well-powered observational study is that unmeasured differences between the groups may have accounted for differences in outcome. The authors used several techniques, including propensity analysis, to adjust for factors that might independently reduce the risk of death for patients receiving β-blockers compared with control subjects. However, several database limitations leave open the possibility of residual confounding. First, the investigators did not know the date of surgery and defined perioperative use of β-blockers as prescription within an arbitrary time period during the hospital admission. Second, they lacked information regarding indications for β-blockers, which may have been withheld from more unstable patients. Finally, they lacked data regarding preoperative use of β-blockers, which raises the possibility that some patients in the control group experienced adverse consequences of withdrawal.

The observed relative risk or odds ratio for most treatments tends to be similar across varying baseline risks, whereas absolute risk reduction is generally greater for higher-risk patients.1 Studies of secondary prevention of myocardial infarction with β-blockers2 and statins3 have demonstrated this phenomenon. However, in this study the odds ratio ranged from harmful to highly beneficial as the baseline risk increased from low to high. This unexpected finding is not easily explained, but it suggests that baseline cardiac risk modifies the effect of β-blockers. One possible explanation is that harmful effects of perioperative β-blockade outweigh any small advantages for lower-risk patients.

Practice implications: This study presents real-world observational data about the use of β-blockers to improve perioperative outcomes and provides limited additional support for their use in this setting. Because of design limitations, however, clinicians should interpret the conclusions cautiously. The results of 2 randomized controlled trials currently underway are awaited with anticipation.

References

  1. 1.↵
    McAlister F. Commentary: relative treatment effects are consistent across the spectrum of underlying risks... usually. Int J Epidemiol 2002;31:76-7.
    OpenUrlFREE Full Text
  2. 2.↵
    The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Simes J, Furberg C, Braunwald E, Davis B, Ford I, Tonkin A, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 2002;23:207-15.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 173 (8)
CMAJ
Vol. 173, Issue 8
11 Oct 2005
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (pp 985-996)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does β-blocker prophylaxis improve survival after major noncardiac surgery?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Marius Terblanche, Neill K.J. Adhikari, Damon C. Scales
CMAJ Oct 2005, 173 (8) 874; DOI: 10.1503/cmaj.051134

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Marius Terblanche, Neill K.J. Adhikari, Damon C. Scales
CMAJ Oct 2005, 173 (8) 874; DOI: 10.1503/cmaj.051134
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Drugs: cardiovascular system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire